AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 295 min read$WST

West (WST) Q3 2026 Earnings Call Transcript

West (WST) reported Q3 2026 revenues of $874M, up 12% organically, and adjusted EPS of $2.66, up 36%. Proprietary Products grew 16.6%, led by HVP Components (20%) and Delivery Devices (26%). West Vantage declined 7% but outperformed expectations. The company raised full-year guidance, citing strong market demand and strategic customer relationships.

Original reporting
finance.yahoo.com
Published Oct 29, 2026, 5:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 5:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
West (WST) Q3 2026 Earnings Call Transcript — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$WSTBullishMed
01

Why it matters

Earnings beat and raised guidance suggest near‑term upside, while segment mix shifts and cyber‑incident recovery provide nuance.

02

Market read

The earnings release provides fresh quantitative data that can influence trading decisions on WST and related healthcare equipment stocks.

03

What to watch

Potential headwinds from the cyber‑incident recovery and slower growth in West Vantage may temper upside.

Relevance 8/10Novelty 8/10Timing: post‑earnings release today

Background

West Pharmaceutical Services (WST) reported Q3 2026 results, highlighting revenue growth, EPS beat, and segment performance.

Company-level read

Ticker impact

$WSTBullishHigh confidence
Context

Q3 2026 earnings beat expectations with $874M revenue and $2.66 adjusted EPS, raising full-year guidance.

Expected impact

upward pressure as market prices in stronger revenue and EPS

Evidence & confidence

Revenue and EPS both exceeded prior guidance; management highlighted growth in HVP components and upgraded outlook.

Market effects

Sector

Strong performance in drug‑handling equipment may boost related biotech and pharma equipment stocks.

Regional

European regulatory upgrades could lift other HVP suppliers in the region.

Global

Positive earnings from a major US medical‑device player supports broader healthcare sector sentiment.

Counterpoint

What could challenge this read

If guidance upgrades are overly optimistic, a pull‑back in HVP demand could pressure the stock.

Key entities

  • Company
    West Pharmaceutical Services

    US‑listed medical‑device manufacturer (ticker WST).

  • Executive
    Bob McMahon

    West CFO presenting the earnings details.

Read at source← All news

StoryWest Pharmaceutical Services posts strong Q3 2026 results and lifts full‑year outlook

Also covered by

5 outlets

Related articles

OCT 31
$WSTHighAI 8/10

What West Pharmaceutical Services (WST) Said on Its Q3 Earnings Call

West Pharmaceutical Services reported Q3 revenue of $874M, up 8.7%, with adjusted EPS increasing 36% to $2.66. Strong demand for biologics and GLP-1 therapies drove growth, particularly in proprietary products. The company raised its 2026 outlook, forecasting revenue of $3.41B-$3.42B and adjusted EPS of $9.38-$9.48. West is also expanding HVP capacity and maintaining dividend and share repurchase programs.

finance.yahoo.com2 min
OCT 29
$WSTMed

West Pharmaceutical Services, Inc. Q3 2026 Earnings Call Summary

West Pharmaceutical Services reported Q3 2026 earnings, highlighting 16.6% growth in proprietary products, driven by HVP components and GLP-1 treatments. Gross margins expanded by 310 basis points due to a shift toward high-value products. The company raised full-year organic growth guidance to 11.3%-11.6% and announced an 18% dividend increase. Management discussed strategic shifts, including divestitures and capital investments in HVP capacity.

finance.yahoo.com6 min
OCT 29
$WSTMedAI 8/10

West Pharmaceutical Services Inc (WST) (Q3 2026) Earnings Call Highlights: Record Margins

West Pharmaceutical Services reported Q3 2026 earnings with record margins, but faced revenue declines in the West Vantage segment and a planned divestiture headwind. Free cash flow decreased 5% year-over-year. CEO Michel Lagarde emphasized strong organic growth prospects and high M&A criteria. GLP-1 revenue growth is expected to decelerate due to tough comparisons. The company anticipates continued margin expansion and plans to invest in high-return HVP areas.

finance.yahoo.com3 min